Nalaganje...
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Intravenous brentuximab vedotin (ADCETRIS(®)) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin...
Shranjeno v:
| izdano v: | Drugs |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7102329/ https://ncbi.nlm.nih.gov/pubmed/28190142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-017-0705-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|